LAVA Therapeutics (LAVA) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free LAVA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineStrong Buy Rating for LAVA Therapeutics on Promising Clinical and Financial Outlookmarkets.businessinsider.com - March 21 at 9:39 PMLAVA Therapeutics Full Year 2023 Earnings: Revenues Disappointuk.finance.yahoo.com - March 21 at 11:38 AMLVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 20 at 1:14 PMLiverpool XI vs Manchester United: Starting lineup, confirmed team news, injury latest for FA Cup todaymsn.com - March 17 at 3:20 PMLVTX Apr 2024 2.500 callfinance.yahoo.com - March 16 at 10:20 AMLAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)finance.yahoo.com - March 5 at 8:45 AMPRGS, EVER and LVTX are among after hour moversseekingalpha.com - February 26 at 10:30 PMStrong Buy Rating for LAVA Therapeutics Amid Strategic Partnerships and Promising Clinical Advancementsmarkets.businessinsider.com - February 2 at 8:15 PMWhy Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - January 25 at 4:39 PMDow Surges Over 100 Points; US GDP Growth Tops Estimatesbenzinga.com - January 25 at 11:31 AMWhy Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?msn.com - January 25 at 11:31 AMNew Alzheimer’s Treatment Accelerates Removal of Plaque From The Brain In Clinical Trialsmsn.com - January 15 at 3:00 PMPsychedelics gave terminal patients relief from their intense anxietymsn.com - January 13 at 3:04 PMAnalysts Are Bullish on These Healthcare Stocks: Genelux Corp. (GNLX), Calliditas Therapeutics (CALT)markets.businessinsider.com - November 27 at 10:23 PMLAVA Therapeutics N.V.: Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 16 at 8:10 AMMemo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officerbusinesswire.com - November 16 at 8:10 AMLAVA Therapeutics GAAP EPS of -$0.34 beats by $0.14msn.com - November 16 at 8:10 AMLava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 16 at 8:10 AMK36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officerfinance.yahoo.com - November 15 at 10:04 AMAnalysts Are Bullish on These Healthcare Stocks: US Physical Therapy (USPH), Calliditas Therapeutics (CALT)markets.businessinsider.com - September 21 at 12:55 PMDelveInsight Highlights Major Advances, Transformative Therapies, and 55+ Leading Players Wheeling the Chronic Lymphocytic Leukemia Pipeline Landscapebenzinga.com - September 18 at 7:46 PMPhiladelphia-area life sciences firms have now cut more than 500 jobs since the start of 2022bizjournals.com - September 6 at 10:30 PMLAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 9:00 AMWhat 5 Analyst Ratings Have To Say About LAVA Therapeuticsmarkets.businessinsider.com - August 23 at 6:05 PMLAVA Therapeutics (LVTX) Gets a Buy from JMP Securitiesmarkets.businessinsider.com - August 23 at 1:56 AMLAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimatesfinance.yahoo.com - August 22 at 3:34 PMLAVA Therapeutics GAAP EPS of -$0.48 beats by $0.02, revenue of $5.14Mmsn.com - August 22 at 3:34 PMLAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conferencefinance.yahoo.com - August 14 at 8:55 AMLAVA Therapeutics BV (LVRX)investing.com - July 29 at 10:15 AMGene therapy developer SwanBio to narrow research focus, lay off half its workforcebizjournals.com - June 29 at 2:11 PMAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and LAVA Therapeutics (LVTX)markets.businessinsider.com - June 15 at 4:49 AMLava Therapeutics shares tumble on move to narrow research focusbizjournals.com - June 14 at 3:47 PMLAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runwayfinance.yahoo.com - June 14 at 9:37 AMLAVA Therapeutics First Quarter 2023 Earnings: US$0.53 loss per share (vs US$0.41 loss in 1Q 2022)finance.yahoo.com - June 9 at 9:57 AMLAVA Therapeutics N.V.: LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Resultsfinanznachrichten.de - June 8 at 8:51 AMLAVA Therapeutics Q1 EPS $(0.53) Misses $(0.52) Estimate, Sales $1.22M Up From $1.00M YoYbenzinga.com - June 8 at 8:51 AMRecap: LAVA Therapeutics Q1 Earningsmsn.com - June 8 at 8:51 AMLAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - June 8 at 8:51 AMLava Therapeutics up 26% as J&J chooses antibody candidate for developmentmsn.com - June 2 at 2:29 PMLava Therapeutics Boils Up Thanks to New Dealmsn.com - June 2 at 2:29 PMLAVA Therapeutics Shares Climb 26% After Janssen Selects Candidate for Cancer Researchmarketwatch.com - June 1 at 11:28 PMGDRX, EVBG and BRZE are among after hour moversseekingalpha.com - June 1 at 6:27 PMLAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Developmentfinance.yahoo.com - June 1 at 6:27 PMJefferies Remains a Buy on LAVA Therapeutics (LVTX)markets.businessinsider.com - May 25 at 8:14 AMZelda fans are curious about one character’s whereabouts in Tears of the Kingdommsn.com - April 19 at 2:23 AMLAVA Therapeutics (LVTX) Receives a Buy from SVB Securitiesmarkets.businessinsider.com - April 14 at 2:18 AMLAVA Therapeutics N.V.: LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officerfinanznachrichten.de - February 6 at 7:37 AMLAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officertechnews.tmcnet.com - February 6 at 7:37 AMAnalysts Are Bullish on Top Healthcare Stocks: KalVista Pharmaceuticals (KALV), Keros Therapeutics (KROS)markets.businessinsider.com - December 14 at 1:59 AMCan LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?finance.yahoo.com - November 25 at 4:42 PM Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… LAVA Media Mentions By Week LAVA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LAVA News Sentiment▼0.000.83▲Average News Sentiment LAVA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LAVA Articles This Week▼00▲LAVA Articles Average Week Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LAVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LAVA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics NV Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.